肿瘤第一线 · 学术知识传播

MedSci主页 / 所有栏目 / 肿瘤第一线 · 学术知识传播

结直肠癌患者血清CEA.CA199的表达变化与肝转移的多因素相关性分析

2021-11-19 石援援 石援援

临床上许多结直肠癌患者在初诊时已存在肝脏转移,结直肠血液回流的解剖学决定了肝脏是其主要转移部位。如何早期发现和诊断结直肠癌肝转移是需致力研究的方向。吴媛媛等研究发现大肠癌肝转移与患者病程、肿瘤浸润深度

临床上许多结直肠癌患者在初诊时已存在肝脏转移,结直肠血液回流的解剖学决定了肝脏是其主要转移部位。如何早期发现和诊断结直肠癌肝转移是需致力研究的方向。吴媛媛等研究发现大肠癌肝转移与患者病程、肿瘤浸润深度、分化程度、淋巴结转移、患者血清CEA、CA199水平相关,应针对相关因素积极治疗。


本研究发现血清CEA及CA199在结直肠癌患者中的表达与患者性别、年龄、肿瘤的大小、部位以及病程均无明显相关性,但与肿瘤的分化程度、浸润深度密切相关,血清CEA、CA199阳性的患者侵袭力强,更易侵透浆膜层、肿瘤恶性程度高、分化程度低,易发生远处转移。CEA是一种肿瘤胚胎性抗原,属于免疫球蛋白G超基因家族的成员,妊娠期CEA常出现于胎儿消化系统中,胎儿出生后其浓度明显下降,但其在很多成人的肿瘤组织均有所表达,特别是消化道肿瘤组织,其表达明显升高6,71CEA多存在于消化器官内胚叶上皮发生的癌细胞,可随着肿瘤细胞的老化逐渐脱落,少量可进入血液,多数沿着管腔排出,血浆中CEA的升高在肿瘤发病的晚期表现明显即病期越晚、恶性程度越高时其血清水平越高。CA199是199年从人结肠癌细胞株中提取出来的一种糖蛋白,是一种单克隆抗体识别的肿瘤标志物,细胞癌变时,其抗原从细胞表面脱落在血中可检测到其抗原的含量变化,使其成为临床肿瘤诊断指标之一,目前在临床上主要用于消化道恶性肿瘤的早期诊断81CA199在结直肠癌肝转移患者中的异常表达,可通过某种糖脂序列影响细胞间的相互识别、粘着,促使肿瘤细胞的浸润和转移。


本研究结果显示,大肠癌发生肝转移患者CEA、CA199阳性率显著高于无肝转移患者(P<0.05),表明CEA和CA199表达对大肠癌肝转移有重要预测价值CEA作为较为常见的肿瘤标志物,在肿瘤术后复发敏感性很高,往往早于相关辅助检查等。研究表明CEA在肿瘤发生的各个阶段均起着重要的作用。有学者发现(101直肠癌患者血清CEA水平与肝转移的发生密切相关,CEA在肿瘤的侵袭转移过程中发挥作用。钟武11等研究发现,血清EA、CA19-9与大肠癌肝转移密切相关,二者浓度同时升高往往提示预后不良。本研究结果认为联合检测CEA与CA199的表达对于预测结直肠癌肝转移患者的生存期更有价值。朱信强等研究指出,无论是单因素还是多因素分析,均能得出CEA及C199是影响结直肠癌肝转移的独立危险因素,这与本研究结果稍有差别本研究应用COX模型进行多因素分析发现,血清CA199为结直肠癌肝转移患者总生存率的独立预测因素,而血清CEA为非独立预测因素,说明在结直肠癌肝转移生存期的预测上,虽然血清CEA的灵敏度很高,但血清CA199以较高的特异性成为结直肠癌肝转移患者总生存率的独立预测因素。


综上所述,结直肠癌患者血清CEA、CA199表达与肝转移明显相关,检测血清CEA、CA199表达水平对直肠癌肝转移及患者生存率均有重要预测价值。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717865, encodeId=35121e17865d6, content=<a href='/topic/show?id=9513393583' target=_blank style='color:#2F92EE;'>#CA199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3935, encryptionId=9513393583, topicName=CA199)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f9432471149, createdName=makuansheng, createdTime=Fri Jan 21 20:26:19 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838007, encodeId=0cae183800ef7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon May 23 11:26:19 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443874, encodeId=bb6914438e4ac, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453604, encodeId=5ae2145360419, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488656, encodeId=76e9148865650, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523664, encodeId=fbd215236643c, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=)]
    2022-01-21 makuansheng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1717865, encodeId=35121e17865d6, content=<a href='/topic/show?id=9513393583' target=_blank style='color:#2F92EE;'>#CA199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3935, encryptionId=9513393583, topicName=CA199)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f9432471149, createdName=makuansheng, createdTime=Fri Jan 21 20:26:19 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838007, encodeId=0cae183800ef7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon May 23 11:26:19 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443874, encodeId=bb6914438e4ac, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453604, encodeId=5ae2145360419, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488656, encodeId=76e9148865650, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523664, encodeId=fbd215236643c, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1717865, encodeId=35121e17865d6, content=<a href='/topic/show?id=9513393583' target=_blank style='color:#2F92EE;'>#CA199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3935, encryptionId=9513393583, topicName=CA199)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f9432471149, createdName=makuansheng, createdTime=Fri Jan 21 20:26:19 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838007, encodeId=0cae183800ef7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon May 23 11:26:19 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443874, encodeId=bb6914438e4ac, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453604, encodeId=5ae2145360419, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488656, encodeId=76e9148865650, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523664, encodeId=fbd215236643c, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1717865, encodeId=35121e17865d6, content=<a href='/topic/show?id=9513393583' target=_blank style='color:#2F92EE;'>#CA199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3935, encryptionId=9513393583, topicName=CA199)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f9432471149, createdName=makuansheng, createdTime=Fri Jan 21 20:26:19 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838007, encodeId=0cae183800ef7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon May 23 11:26:19 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443874, encodeId=bb6914438e4ac, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453604, encodeId=5ae2145360419, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488656, encodeId=76e9148865650, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523664, encodeId=fbd215236643c, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1717865, encodeId=35121e17865d6, content=<a href='/topic/show?id=9513393583' target=_blank style='color:#2F92EE;'>#CA199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3935, encryptionId=9513393583, topicName=CA199)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f9432471149, createdName=makuansheng, createdTime=Fri Jan 21 20:26:19 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838007, encodeId=0cae183800ef7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon May 23 11:26:19 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443874, encodeId=bb6914438e4ac, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453604, encodeId=5ae2145360419, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488656, encodeId=76e9148865650, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523664, encodeId=fbd215236643c, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=)]
    2021-11-22 shizhenshan
  6. [GetPortalCommentsPageByObjectIdResponse(id=1717865, encodeId=35121e17865d6, content=<a href='/topic/show?id=9513393583' target=_blank style='color:#2F92EE;'>#CA199#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3935, encryptionId=9513393583, topicName=CA199)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f9432471149, createdName=makuansheng, createdTime=Fri Jan 21 20:26:19 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1838007, encodeId=0cae183800ef7, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon May 23 11:26:19 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443874, encodeId=bb6914438e4ac, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453604, encodeId=5ae2145360419, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488656, encodeId=76e9148865650, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523664, encodeId=fbd215236643c, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Nov 22 07:26:19 CST 2021, time=2021-11-22, status=1, ipAttribution=)]

相关资讯

综合营养干预对晚期大肠癌化疗患者营养状况及生存质量的影响

营养治疗作为恶性肿瘤多学科综合治疗的重要组成部分,已经越来越受到肿瘤领域专家的高度重视。早期筛查和确定病人的营养不良并及时给予营养干预可以改善患者营养状况,并提高抗肿瘤治疗结局。Hasenberg T

肠外营养支持治疗对围化疗期晚期胃肠道肿瘤患者营养状况及免疫功能的影响

恶性肿瘤往往容易导致营养不良状况发生,大约40%~80%的恶性肿瘤患者存在营养不良约15% 的患者在确诊时6 个月P内体质量下降超过10%,尤以胃肠道或头颈部肿瘤最为常见。胃肠道恶性肿瘤患者营养不良原

不同剂量阿司匹林对改善晚期化疗后结直肠癌患者预后的影响

结直肠癌是由结肠细胞或直肠细胞发生恶性病变演化而成的,近年来发病率呈逐年升高的趋势。结直肠癌的主要治疗方法为的手术治疗,然而由于该病早期症状不明显,约1/3的患者一经确诊便已是晚期,已错过手术最佳治疗